Skip to main content
Top
Published in: Diabetologia 2/2010

01-02-2010 | Article

Risk factors for incident type 2 diabetes in individuals with a BMI of <27 kg/m2: the role of γ-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR)

Authors: A. Gautier, B. Balkau, C. Lange, J. Tichet, F. Bonnet, for the DESIR Study Group

Published in: Diabetologia | Issue 2/2010

Login to get access

Abstract

Aims/hypothesis

Risk factors for incident type 2 diabetes, in particular, hepatic markers, have rarely been studied in leaner individuals. We aimed to identify the metabolic and hepatic markers associated with incident diabetes in men and women with a BMI of <27 kg/m2 and to compare them with those in individuals with a BMI of ≥27 kg/m2.

Methods

Risk factors for 9 year incident diabetes were compared in the French Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Comparisons were made between the 2,947 participants with a BMI of <27 kg/m2 and the 879 with a BMI of ≥27 kg/m2.

Results

There were 92 incident cases of diabetes in individuals with a BMI of <27 kg/m2 and 111 in those with a BMI of ≥27 kg/m2. Among those who were not markedly overweight, classical biological markers were associated with 9 year incident diabetes, glycaemia being the strongest predictor. γ-Glutamyltransferase (GGT), either considered as a continuous variable or at levels ≥20 U/l, was associated with incident diabetes, with a stronger effect in the BMI <27 kg/m2 group: OR 1.59 (95% CI 1.29–1.97, p < 0.001) in comparison with OR 1.07 (95% CI 0.82–1.38, p = 0.63) for those with a BMI of ≥27 kg/m2 (results after adjustment for alcohol intake, alanine aminotransferase, waist circumference and the HOMA insulin resistance index).

Conclusions/interpretation

In individuals with a BMI of <27 kg/m2, GGT was the strongest predictor of diabetes after fasting hyperglycaemia. This association with incident diabetes remained after adjustment for conventional markers of insulin resistance, suggesting potential interactions between GGT, enhanced hepatic neoglucogenesis and/or early alterations of insulin secretion.
Appendix
Available only for authorised users
Literature
1.
go back to reference Edelstein SL, Knowler WC, Bain RP et al (1997) Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701–710CrossRefPubMed Edelstein SL, Knowler WC, Bain RP et al (1997) Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701–710CrossRefPubMed
2.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
3.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
4.
go back to reference Cicero AF, Dormi A, Nascetti S et al (2005) Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 22:1263–1266CrossRefPubMed Cicero AF, Dormi A, Nascetti S et al (2005) Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 22:1263–1266CrossRefPubMed
5.
go back to reference Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM (2003) The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 26:3153–3159CrossRefPubMed Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM (2003) The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 26:3153–3159CrossRefPubMed
6.
go back to reference Magliano DJ, Barr EL, Zimmet PZ et al (2008) Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 31:267–272CrossRefPubMed Magliano DJ, Barr EL, Zimmet PZ et al (2008) Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 31:267–272CrossRefPubMed
7.
go back to reference Bertrais S, Balkau B, Vol S et al (1999) Relationships between abdominal body fat distribution and cardiovascular risk factors: an explanation for women’s healthier cardiovascular risk profile. The D.E.S.I.R. Study. Int J Obes Relat Metab Disord 23:1085–1094CrossRefPubMed Bertrais S, Balkau B, Vol S et al (1999) Relationships between abdominal body fat distribution and cardiovascular risk factors: an explanation for women’s healthier cardiovascular risk profile. The D.E.S.I.R. Study. Int J Obes Relat Metab Disord 23:1085–1094CrossRefPubMed
8.
go back to reference Balkau B, Lange C, Fezeu L et al (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 31:2056–2061CrossRefPubMed Balkau B, Lange C, Fezeu L et al (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 31:2056–2061CrossRefPubMed
9.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
10.
go back to reference Hu G, Lindstrom J, Valle TT et al (2004) Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med 164:892–896CrossRefPubMed Hu G, Lindstrom J, Valle TT et al (2004) Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med 164:892–896CrossRefPubMed
11.
go back to reference The Diabetes Prevention Program Research Group (2006) Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring) 14:2107–2117CrossRef The Diabetes Prevention Program Research Group (2006) Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring) 14:2107–2117CrossRef
12.
go back to reference Andre P, Balkau B, Born C, Charles MA, Eschwege E (2006) Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 49:2599–2603CrossRefPubMed Andre P, Balkau B, Born C, Charles MA, Eschwege E (2006) Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 49:2599–2603CrossRefPubMed
13.
go back to reference Perry IJ, Wannamethee SG, Shaper AG (1998) Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21:732–737CrossRefPubMed Perry IJ, Wannamethee SG, Shaper AG (1998) Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21:732–737CrossRefPubMed
14.
go back to reference Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J (2004) gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20, 158 middle-aged men and women. J Clin Endocrinol Metab 89:5410–5414CrossRefPubMed Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J (2004) gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20, 158 middle-aged men and women. J Clin Endocrinol Metab 89:5410–5414CrossRefPubMed
15.
go back to reference Lee DH, Ha MH, Kim JH et al (2003) Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia 46:359–364CrossRefPubMed Lee DH, Ha MH, Kim JH et al (2003) Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia 46:359–364CrossRefPubMed
16.
go back to reference Nakanishi N, Suzuki K, Tatara K (2004) Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 27:1427–1432CrossRefPubMed Nakanishi N, Suzuki K, Tatara K (2004) Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 27:1427–1432CrossRefPubMed
17.
go back to reference Wannamethee SG, Shaper AG, Lennon L, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28:2913–2918CrossRefPubMed Wannamethee SG, Shaper AG, Lennon L, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28:2913–2918CrossRefPubMed
18.
go back to reference Sato KK, Hayashi T, Nakamura Y et al (2008) Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 31:1230–1236CrossRefPubMed Sato KK, Hayashi T, Nakamura Y et al (2008) Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 31:1230–1236CrossRefPubMed
19.
go back to reference Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR Jr (2007) A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem 53:1092–1098CrossRefPubMed Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR Jr (2007) A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem 53:1092–1098CrossRefPubMed
20.
go back to reference Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA (2009) Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32:741–750CrossRefPubMed Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA (2009) Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32:741–750CrossRefPubMed
21.
go back to reference Kim CH, Park JY, Lee KU, Kim JH, Kim HK (2009) Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 25:64–69CrossRefPubMed Kim CH, Park JY, Lee KU, Kim JH, Kim HK (2009) Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 25:64–69CrossRefPubMed
22.
go back to reference Wallace TM, Utzschneider KM, Tong J et al (2007) Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. Diabetes Care 30:2673–2678CrossRefPubMed Wallace TM, Utzschneider KM, Tong J et al (2007) Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. Diabetes Care 30:2673–2678CrossRefPubMed
23.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
24.
go back to reference Vozarova B, Stefan N, Lindsay RS et al (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889–1895CrossRefPubMed Vozarova B, Stefan N, Lindsay RS et al (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889–1895CrossRefPubMed
25.
go back to reference Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163CrossRefPubMed Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163CrossRefPubMed
26.
go back to reference Hsiao JY, Wang CL, Hsia PJ et al (2007) Decreased insulin secretion and insulin sensitivity are associated with liver function in subjects with fasting glucose between 100 and 109 mg/dL in Taiwanese population. Pancreas 35:343–347CrossRefPubMed Hsiao JY, Wang CL, Hsia PJ et al (2007) Decreased insulin secretion and insulin sensitivity are associated with liver function in subjects with fasting glucose between 100 and 109 mg/dL in Taiwanese population. Pancreas 35:343–347CrossRefPubMed
27.
go back to reference Alvarsson M, Wajngot A, Cerasi E, Efendic S (2005) K-value and low insulin secretion in a non-obese white population: predicted glucose tolerance after 25 years. Diabetologia 48:2262–2268CrossRefPubMed Alvarsson M, Wajngot A, Cerasi E, Efendic S (2005) K-value and low insulin secretion in a non-obese white population: predicted glucose tolerance after 25 years. Diabetologia 48:2262–2268CrossRefPubMed
28.
go back to reference Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58:1212–1221CrossRefPubMed Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58:1212–1221CrossRefPubMed
29.
go back to reference Lee DH, Blomhoff R, Jacobs DR Jr (2004) Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 38:535–539CrossRefPubMed Lee DH, Blomhoff R, Jacobs DR Jr (2004) Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 38:535–539CrossRefPubMed
30.
go back to reference Tang C, Han P, Oprescu AI et al (2007) Evidence for a role of superoxide generation in glucose-induced beta-cell dysfunction in vivo. Diabetes 56:2722–2731CrossRefPubMed Tang C, Han P, Oprescu AI et al (2007) Evidence for a role of superoxide generation in glucose-induced beta-cell dysfunction in vivo. Diabetes 56:2722–2731CrossRefPubMed
31.
go back to reference Park K, Gross M, Lee DH et al (2009) Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care 32:1302–1307CrossRefPubMed Park K, Gross M, Lee DH et al (2009) Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care 32:1302–1307CrossRefPubMed
Metadata
Title
Risk factors for incident type 2 diabetes in individuals with a BMI of <27 kg/m2: the role of γ-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR)
Authors
A. Gautier
B. Balkau
C. Lange
J. Tichet
F. Bonnet
for the DESIR Study Group
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1602-6

Other articles of this Issue 2/2010

Diabetologia 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine